SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemiaConstanze Schneider, Jindřich Činátl, Wolfgang Hartmann et al.|Nature Medicine|2016Cited by 185
Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid LeukemiaSebastian Mohr, Thomas Oellerich|Cancer Cell|2017Cited by 116
An overview and a roadmap for artificial intelligence in hematology and oncologyWiebke Rösler, Jakob Nikolas Kather, Michael Altenbuchinger et al.|Journal of Cancer Research and Clinical Oncology|2023Cited by 84
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AMLThomas Oellerich, Jindřich Činátl|Nature Communications|2019Cited by 82
CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cellsTobias Bexte, Evelyn Ullrich, Nawid Albinger et al.|Nature Communications|2024Cited by 71